Chemical formula: C₂₂H₂₂N₆O₃ Molecular mass: 418.448 g/mol PubChem compound: 71621331
Futibatinib is indicated for:
Population group: only adults (18 years old or older)
Futibatinib monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Futibatinib is contraindicated in the following cases:
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
